Summary of NOTICE OF PROPOSED SOLE SOURCE PURCHASE 926-494

This is a Sole Source Notice issued by the Mississippi Department of Mental Health for the procurement of FDA-cleared Clozapine Test Kits. The notice announces the department's intention to purchase these medical testing kits through a sole source acquisition rather than through competitive bidding. Clozapine is an antipsychotic medication requiring regular monitoring, and the test kits are essential for therapeutic drug monitoring and patient safety protocols. The notice provides interested parties with an opportunity to submit written objections to the sole source justification within the specified timeframe, typically allowing 15 calendar days from the notice publication date for potential vendors to challenge the sole source determination if they believe they can provide equivalent products or services.

The procurement is driven by the clinical necessity of maintaining continuity in laboratory testing procedures for patients currently receiving Clozapine therapy within the state's mental health system. The sole source designation suggests that the selected vendor's product has been determined to be the only suitable option available that meets the department's technical and clinical requirements. Interested parties should direct any objections or inquiries to the Mississippi Department of Mental Health's procurement office as outlined in the notice, providing specific documentation of their capability to supply equivalent FDA-cleared products if contesting the sole source justification.